What Ethicon changed

• Added full "Essential Product Information" for SURGICEL™ Powder.
• Included specific indications for use in capillary, venous, and small arterial bleeding.
• Added instructions for the SURGICEL™ Endoscopic Applicator.
• Listed extensive contraindications, including warnings against use in large vessel defects or for adhesion prevention.
• Detailed potential adverse reactions such as paralysis, nerve damage, and foreign body reactions.
• Added a new reference to a June 2024 US Market & Share Insights Report.

The website now includes detailed clinical guidelines and safety warnings for SURGICEL™ Powder. This provides surgeons with specific instructions on how to use the product in both open and endoscopic procedures, while highlighting critical risks like nerve damage or device migration.

• All product information for SURGICEL Powder Absorbable Hemostat was removed.
• Detailed sections on indications, warnings, and contraindications are gone.
• The page now shows a security verification message for jnjmedtech.com.
• Technical support contact information and reference links were deleted.

The detailed safety information, usage instructions, and warnings for SURGICEL Powder are no longer visible on this page. This may indicate a technical error, a website migration, or a temporary removal of product documentation.

• Removed the copyright notice for Johnson & Johnson and its affiliates.
• Replaced the reference number "406421" with a new regulatory code: "US_SRG_ALLS_406421".

The company updated its internal document identification system. This usually happens when a company refreshes its compliance records or changes how it tracks marketing materials for medical devices.